Apis Capital Advisors’ Apis Flagship Fund had a strong performance in Q4 2025, up 10.0% net for the quarter and gaining 55.1% for the full year, outperforming the MSCI ACWI global benchmark. Technology and Healthcare led quarterly returns, with a focus on bottom-up stock selection and non-U.S. markets for future potential returns.

uniQure (NASDAQ: QURE) is a gene therapy company with a one-month return of 0.44%, trading between $7.76 and $71.50 over the last 52 weeks. In Q4 2025, uniQure detracted about 1.1% in the Apis Flagship Fund’s investor letter, attributed to technical pause post strong performance.

uniQure (NASDAQ: QURE) is not among the 30 Most Popular Stocks Among Hedge Funds, with 59 hedge fund portfolios holding it at the end of Q3 2025. While acknowledging its potential, the focus is on AI stocks for higher returns. For an undervalued AI stock benefiting from Trump-era tariffs, see the free report on the best short-term AI stock.

Read more at Yahoo Finance: Here’s Why uniQure (QURE) Declined in Q4